CAT. NO. DCA0007
LC-MG-4
LC-MG-4 is an infigratinib-derived research compound bearing an unsubstituted acrylamide handle. The paper reports moderate FGFR2 degradation in KATO III cells at 1 µM for 12 h. It served as the reference scaffold for testing changes to the Michael-acceptor group.
Pack sizes, price, purity, stock and lead time: please inquire.
Request a quote / synthesis assessmentPublished cellular evidence
Reported assay conditions
KATO III cells; 1 µM; 12 h; FGFR2 Western blot; DMSO control.
Reported result
LC-MG-4 is an infigratinib-derived research compound bearing an unsubstituted acrylamide handle. The paper reports moderate FGFR2 degradation in KATO III cells at 1 µM for 12 h. It served as the reference scaffold for testing changes to the Michael-acceptor group.
Source locations: Main Fig. 1C–D and 3A–B; sections 2.2 and 2.4
A compound-specific DC50, antiproliferative IC50, E3-ligase mechanism and in vivo efficacy were not established for this analogue in the cited study.
For research use only. Published findings depend on the reported experimental conditions and do not guarantee product performance. No clinical use.
Identity and specifications
| CAT. NO. | DCA0007 |
|---|---|
| Molecular formula | C27H29Cl2N7O4 |
| Molecular weight | 586.48 |
| Stereochemistry | Terminal alkene; no stereocentres |
| Chemical form | Neutral parent; no counterion assigned |
| SMILES | C=CC(=O)N1CCN(c2ccc(Nc3cc(N(C)C(=O)Nc4c(Cl)c(OC)cc(OC)c4Cl)ncn3)cc2)CC1 |
Molecular formula and average molecular weight are calculated from the source-verified structure; molecular weight unit: g/mol.
References
Cao X, Huang X, Song C, Shi S, Zhu Y, Zheng L, Liang G, Chen L. Converting FGFR inhibitors into selective covalent molecular glue degraders via transposable gluing handles. European Journal of Medicinal Chemistry 316 (2026), 119034. doi:10.1016/j.ejmech.2026.119034.
Source locations: Main Fig. 1C–D and 3A–B; experimental compound LC-MG-4, p. 9; supplied SI section 8.
Published online: 2 June 2026.